Eli Lilly and Company (LLY) Stock Price, Quote & News

Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncolog...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 317 276 2000

Website: www.lilly.com

Address:

Lilly Corporate Center, Indianapolis, United States

josh2017 Aug. 1 at 12:27 PM

$HIMS $LLY $NVO $TDOC $UNH ”US Plan Medicare, Medicaid coverage for weight-loss drugs” Washington Post.

0 · Reply

OpenOutcrier Aug. 1 at 12:27 PM

$NVO $LLY $HIMS Eli Lilly stock rises, Novo Nordisk shares jump on potential Medicare coverage https://ooc.bz/l/72294

0 · Reply

Gergely_Blasko Aug. 1 at 12:24 PM

$NVO catalysts: - FDA approval TODAY for Esperoct (extended half-life recombinant factor VIII) – targeting the $9B hemophilia market. - Oral Wegovy likely approved in 2025 – first widely available oral GLP-1 for weight loss. - 2026 launch of Amycretin – dual agonist (GLP-1 + amylin), potentially stronger efficacy + weight loss durability. - 2027 Medicaid inclusion for anti-obesity drugs = major tailwind. (Today's BREAKING NEWS) Tariff-proof: U.S.-based manufacturing already in place for key drugs. Main rival $LLY is just starting to build U.S. facilities. Strong fundamentals: ✔️ Excellent cash flow ✔️ R&D with quantum computing ✔️ Multiple long-term growth vectors $NVO = best-in-class obesity & metabolic megatrend play. Oversold, overly shorted with huge incoming short squeeze today. Extremely

0 · Reply

PUTZ549 Aug. 1 at 11:49 AM

$UNH $NVO $LLY $FSLR here comes the Tech rotation imo

0 · Reply

Pep1234 Aug. 1 at 11:47 AM

$HIMS $LLY $NVO https://www.reuters.com/business/healthcare-pharmaceuticals/us-plans-medicare-medicaid-coverage-weight-loss-drugs-washington-post-reports-2025-08-01/

0 · Reply

EMOTIONAL_TRADER_ Aug. 1 at 11:46 AM

$NVO $LLY EGYPTIAN PRICED DRUGS FOR AMERICAN CONSUMERS

0 · Reply

Tom2772 Aug. 1 at 11:36 AM

$NVO $HIMS $WW $LLY $NVDA – Alhemo targets a $9.09B U.S. hemophilia prophylaxis market (projected 2030 value) by addressing adherence challenges with its prefilled pen-injector and competing directly with Hemlibra and Hyrnpavzi. – Analysts forecast $1–2B annual sales by 2030 with 20–30% market penetration, positioning Novo Nordisk to capitalize on the 6.9% CAGR growth in prophylactic treatment adoption. https://www.ainvest.com/news/alhemo-fda-approval-hemophilia-inhibitors-game-changer-novo-nordisk-rare-disease-portfolio-2508/

1 · Reply

Tom2772 Aug. 1 at 11:33 AM

$NVO $HIMS $WW $LLY $NVDA 11:21 PM July 31 2025 FDA approves Alhemo® as once-daily prophylactic treatment to prevent or reduce the frequency of bleeding episodes for adults and children 12 years of age and older with hemophilia A or B (HA/HB) without inhibitors FDA approval is based on phase 3 trial data (explorer8), which established the safety and efficacy of Alhemo® (concizumab-mtci) injection in people 12 years and older with hemophilia A or B (HA/HB) without inhibitors1 Results showed a 79% reduction in annualized bleeding rate (ABR) in patients with HB without inhibitors and an 86% reduction in patients with HA without inhibitors, respectively, using Alhemo® prophylaxis compared to no prophylaxis2 Alhemo® was the first subcutaneous injectable pen of its kind for patients living with HA and HB with inhibitors and is now approved for those living without inhibitors1 https://www.novonordisk-us.com/media/news-archive/news-details.html?id=916409&utm_medium=organic&utm_source=twitter&utm_campaign=2025-media-release&utm_content=nni-alhemo-sci_inn

0 · Reply

Blink182rulez Aug. 1 at 11:11 AM

$VKTX this is good news for $VKTX $LLY bad news for $HIMS

0 · Reply

bhrt Aug. 1 at 11:09 AM

$LLY https://www.reuters.com/business/healthcare-pharmaceuticals/us-plans-medicare-medicaid-coverage-weight-loss-drugs-washington-post-reports-2025-08-01/

0 · Reply

President Trump demands drugmakers slash prices within 60 days

ABBV ABT ALNY AMGN ARGX AZN BAX

Jul 31, 2025, 3:35 PM EDT - 17 hours ago

Pharma Companies Should Immediately Cut Down Drug Prices, Trump Says

ABBV AMGN AZN BMY GILD GSK JNJ

Jul 31, 2025, 3:00 PM EDT - 17 hours ago

Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days.

ABBV AMGN AZN BMY GILD GSK JNJ

Jul 31, 2025, 2:28 PM EDT - 18 hours ago

Trump pressures 17 pharma CEOs to cut US drug prices

ABBV AMGN AZN BMY GILD GSK JNJ

Jul 31, 2025, 2:19 PM EDT - 18 hours ago

Trump posts letters to 17 pharmaceutical companies about drug prices

ABBV GILD PFE AMGN AZN BMY GSK

Jul 31, 2025, 1:48 PM EDT - 18 hours ago

Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days

ABBV AMGN AZN BMY GILD GSK JNJ

Jul 31, 2025, 9:52 AM EDT - 22 hours ago

10 stocks favored to gain up to 30% in a sector that has missed this year's rally

BSX CAH DXCM EW ISRG PODD SYK

Jul 31, 2025, 9:30 AM EDT - 23 hours ago

Eli Lilly Obesity Drug Mounjaro Beats Legacy Trulicity On Cardio-Renal Health

Jul 31, 2025, 8:33 AM EDT - 1 day ago

Elli Lilly Weight-Loss Drug Makes Cardio Advance. More Bad News for Novo Nordisk.

NVO

Jul 31, 2025, 7:31 AM EDT - 1 day ago

Eli Lilly's Mounjaro met goal of cardiovascular benefit in head-to-head trial with Trulicity

Jul 31, 2025, 6:50 AM EDT - 1 day ago

Mounjaro proves more heart protective than Trulicity in trial of Eli Lilly diabetes drugs

Jul 31, 2025, 6:45 AM EDT - 1 day ago

Eli Lilly's Mounjaro shows heart health benefits in head-to-head trial with older diabetes drug Trulicity

Jul 31, 2025, 6:45 AM EDT - 1 day ago

Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease

Jul 30, 2025, 8:01 AM EDT - 2 days ago

Lilly's Kisunla (donanemab-azbt) showed growing benefit over three years in early symptomatic Alzheimer's disease

Jul 29, 2025, 3:49 PM EDT - 2 days ago

Lilly set for strong quarter after Novo profit warning

Jul 29, 2025, 12:41 PM EDT - 2 days ago

What other health conditions are weight-loss drugs being tested for?

NVO

Jul 29, 2025, 9:00 AM EDT - 2 days ago

LTZ Therapeutics Announces Strategic Collaboration with Eli Lilly to Advance Development of its Myeloid Engager Platform for Autoimmune Diseases

Jul 29, 2025, 7:05 AM EDT - 3 days ago

Lilly's cancer drug more effective than AbbVie's in head-to-head study

ABBV

Jul 29, 2025, 6:45 AM EDT - 3 days ago

Lilly's Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, met its primary endpoint in a head-to-head Phase 3 trial versus Imbruvica (ibrutinib) in CLL/SLL

Jul 27, 2025, 5:30 AM EDT - 5 days ago

Thousands of Americans are being forced to switch from Zepbound to Wegovy as a result of new coverage restrictions by CVS Caremark. ‘I just wish they would trust my doctor.

CVS NVO

Jul 25, 2025, 1:49 PM EDT - 6 days ago

3 Pharma Stocks That Aren't Sweating the Coming 200% Drug Tariffs

JNJ NVS

Jul 25, 2025, 12:01 PM EDT - 6 days ago

The Big 3: OKTA, LLY, ADSK

ADSK OKTA

Jul 25, 2025, 9:41 AM EDT - 6 days ago

EU regulator backs Eli Lilly's Alzheimer's drug after initial rejection

Jul 25, 2025, 8:49 AM EDT - 6 days ago

Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk

VERV

Jul 25, 2025, 6:27 AM EDT - 7 days ago

Donanemab receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in early symptomatic Alzheimer's disease

Jul 24, 2025, 12:21 PM EDT - 7 days ago

INSERTING and REPLACING Gate Bioscience Enters into a Collaboration and License Agreement with Lilly to Discover and Develop Molecular Gate Medicines

Jul 24, 2025, 12:08 PM EDT - 7 days ago

Chewy, Eaton and 2 Other Stocks Set to Gain After Earnings, Says Morgan Stanley

CHWY ETN TXN

Jul 24, 2025, 10:00 AM EDT - 7 days ago

Lilly confirms date and conference call for second-quarter 2025 financial results announcement

Jul 24, 2025, 8:48 AM EDT - 7 days ago

This Weight-Loss Stock Sank After Earnings. It's Still a Risk for Eli Lilly, Novo Nordisk.

NVO

Jul 24, 2025, 8:00 AM EDT - 8 days ago

Lilly and Verve announce expiration of Verve tender offer

VERV

Jul 24, 2025, 8:00 AM EDT - 8 days ago

Gate Bioscience Enters into a Collaboration and License Agreement with Lilly to Discover and Develop Molecular Gate Medicines

Jul 23, 2025, 9:57 AM EDT - 8 days ago

Five years after COVID, pharma shares languish in US policy limbo

ABBV ABT ALNY AZN EW MRK NVO

Jul 21, 2025, 10:27 AM EDT - 10 days ago

15 stocks of companies set to grow sales twice as fast as the S&P 500 — analysts love them

CMG COF DXCM FSLR INTU MA MPWR

Jul 21, 2025, 10:00 AM EDT - 10 days ago

Eli Lilly: Competition Melts Away

Jul 20, 2025, 8:00 AM EDT - 12 days ago

Weight loss drugs could be a gamechanger for women with a common hormonal disorder

NVO

Jul 18, 2025, 1:25 PM EDT - 13 days ago

Calls of the Day: Eli Lilly and Materion

MTRN

Jul 11, 2025, 3:30 PM EDT - 20 days ago

Orr: PLTR & NVDA are Overvalued, GOOGL & LLY Great Upcoming Picks

GOOG GOOGL NVDA PLTR

Jul 10, 2025, 4:31 PM EDT - 21 days ago

Eli Lilly Comes Out As ADA Winner

Jul 10, 2025, 12:35 PM EDT - 21 days ago

The Big 3: AVGO, LLY, UBER

AVGO UBER

Jul 9, 2025, 2:55 PM EDT - 22 days ago

Zepbound Powers Eli Lilly's Upbeat Q2 Outlook

Jul 9, 2025, 6:48 AM EDT - 23 days ago

US FDA approves gradual dosing for Lilly Alzheimer's drug

Jul 9, 2025, 6:45 AM EDT - 23 days ago

FDA approves updated label for Lilly's Kisunla (donanemab-azbt) with new dosing in early symptomatic Alzheimer's disease

Jul 8, 2025, 1:41 PM EDT - 23 days ago

Trump threatens impose up to 200% tariff on pharmaceuticals 'very soon'

ABBV JNJ

Jul 7, 2025, 6:48 AM EDT - 25 days ago

Demand for obesity drugs shoots up in India as Lilly, Novo jostle for market share

Jul 7, 2025, 5:30 AM EDT - 25 days ago

Eli Lilly's 3-step strategy to dominate the $95 billion obesity market

Jul 4, 2025, 1:01 AM EDT - 4 weeks ago

Lilly and Novo Are the Kings of Weight-Loss Drugs. The Companies Coming for Their Crowns.

Jul 2, 2025, 8:56 AM EDT - 4 weeks ago

Top 50 High-Quality Dividend Stocks For July 2025

AAPL ACN ALLE AMAT APH CTAS DHI

Jul 1, 2025, 9:02 PM EDT - 4 weeks ago

Top 15 High-Growth Dividend Stocks For July 2025

APH BAC BK DKS DPZ ELV GPN

Jul 1, 2025, 2:53 PM EDT - 4 weeks ago

CVS drops Lilly's Zepbound

CVS

Jun 26, 2025, 6:25 AM EDT - 5 weeks ago

Eli Lilly seen as the stronger bet amid escalating competition with Novo in India

josh2017 Aug. 1 at 12:27 PM

$HIMS $LLY $NVO $TDOC $UNH ”US Plan Medicare, Medicaid coverage for weight-loss drugs” Washington Post.

0 · Reply

OpenOutcrier Aug. 1 at 12:27 PM

$NVO $LLY $HIMS Eli Lilly stock rises, Novo Nordisk shares jump on potential Medicare coverage https://ooc.bz/l/72294

0 · Reply

Gergely_Blasko Aug. 1 at 12:24 PM

0 · Reply

PUTZ549 Aug. 1 at 11:49 AM

$UNH $NVO $LLY $FSLR here comes the Tech rotation imo

0 · Reply

Pep1234 Aug. 1 at 11:47 AM

$HIMS $LLY $NVO https://www.reuters.com/business/healthcare-pharmaceuticals/us-plans-medicare-medicaid-coverage-weight-loss-drugs-washington-post-reports-2025-08-01/

0 · Reply

EMOTIONAL_TRADER_ Aug. 1 at 11:46 AM

$NVO $LLY EGYPTIAN PRICED DRUGS FOR AMERICAN CONSUMERS

0 · Reply

Tom2772 Aug. 1 at 11:36 AM

1 · Reply

Tom2772 Aug. 1 at 11:33 AM

0 · Reply

Blink182rulez Aug. 1 at 11:11 AM

$VKTX this is good news for $VKTX $LLY bad news for $HIMS

0 · Reply

bhrt Aug. 1 at 11:09 AM

$LLY https://www.reuters.com/business/healthcare-pharmaceuticals/us-plans-medicare-medicaid-coverage-weight-loss-drugs-washington-post-reports-2025-08-01/

0 · Reply

ylvje9943 Aug. 1 at 11:06 AM

$WW $LLY $NVDA x.com/InReagle97286/status/1950896119317483539

0 · Reply

Tom2772 Aug. 1 at 11:05 AM

$NVO $HIMS $WW $LLY $NVDA

0 · Reply

US_Bull Aug. 1 at 11:03 AM

$LLY $NVO $XBI $IBB Will pull up the sector today IMO.

0 · Reply

knowthyself Aug. 1 at 11:00 AM

$NVO Trump is allegedly planing to implement a 5-year weight-loss plan. $LLY and $NVO would benefit.

0 · Reply

HOOD02125 Aug. 1 at 10:47 AM

$NVO $LLY 👇🏻👇🏻 x.com/SalamaScob13163/status/1950888852706783651

0 · Reply

kindness123 Aug. 1 at 10:40 AM

$LLY $NVO US plans Medicare, Medicaid coverage for weight-loss drugs, Washington Post reports - https://www.reuters.com/business/healthcare-pharmaceuticals/trump-administration-pilot-coverage-weightloss-drugs-under-medicare-medicaid-2025-08-01/

0 · Reply

kindness123 Aug. 1 at 10:35 AM

$LLY lets go buy red sell green 🤭

0 · Reply

bhrt Aug. 1 at 10:35 AM

$LLY is this just pre market or real move just a bear trap or bull trap ow what the heck 🤪

0 · Reply

EK12 Aug. 1 at 10:21 AM

$LLY The major selloff after the announcement by trump to re-establish MFN (Most Favorite Nation) pricing is what rattled the market yesterday and early this am. LLY will likely navigate arround it just like it did in 2018 (previous Trump administration). Truth is they may lower prices and make up for it in volume especially if $NVO will be tariffed.

1 · Reply

23ChaseColeman23 Aug. 1 at 10:13 AM

$XLV $CURE $UNH $LLY one of the weakest sectors out there

0 · Reply

YearOfTheRabbit Aug. 1 at 10:12 AM

$LLY $NVO Why are we all of a sudden going up ?

3 · Reply

Max9090 Aug. 1 at 9:32 AM

$NVO stock is back to pre wegovy launch. All 3 years gain has been officially wiped. Meanwhile they still make more than 2 times of what they did back then. And $LLY is valued 4.4 times more than novo making 2b less annually hahaha

0 · Reply

Market Cap	720.36B
Revenue (ttm)	45.04B
Net Income (ttm)	10.59B
EPS (ttm)	N/A
PE Ratio	55.45
Forward PE	34.60
Profit Margin	23.51%
Debt to Equity Ratio	2.18

Volume	5,810,200
Avg Vol	3,334,136
Day's Range	N/A - N/A
Shares Out	947.74M
Stochastic %K	5%
Beta	0.40
Analysts	Strong Sell
Price Target	$984.29